Department of Health and Human Services, through National Institutes of Health, awarded Optimeos Life Sciences, Inc. of Princeton, NJ $600,000 under the SBIR program (Phase I), with work starting 2025-08-19 and running to 2027-07-31. It is the only SBIR or STTR award to Optimeos Life Sciences, Inc. in the last two years. Each figure links to the federal record.
The award
| Recipient | Optimeos Life Sciences, Inc. (Princeton, NJ) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase I |
| Amount obligated | $600,000 |
| Period of performance starts | 2025-08-19 |
| Period of performance ends | 2027-07-31 |
| Award number | R43AI188970 (grant, CFDA 93.855) |
| Assistance listing | 93.855, Allergy and Infectious Diseases Research |
| Place of performance | Princeton, Middlesex County, NJ |
| Recipient registry id (UEI) | LSBKUFPKAHW7 |
Want the whole picture on Optimeos Life Sciences, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Optimeos Life Sciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Optimeos Life Sciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
In vivo targeted delivery of nucleic acids to hematopoietic stem cells for treating primary immunodeficiencies - summary in this Phase I SBIR, optimeos will develop an off-the-shelf nanoparticle platform for in vivo stem
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-07-23 | Continuation | 000 | $300,000 |
| 2025-08-19 | New | 000 | $300,000 |
In vivo targeted delivery of nucleic acids to hematopoietic stem cells for treating primary immunodeficiencies - summary in this Phase I SBIR, optimeos will develop an off-the-shelf nanoparticle platform for in vivo stem cell gene therapy, which we will initially apply to treat ada-scid, a severe immune deficiency. We will deliver a DNA payload in nanoparticles targeting hematopoietic stem and progenitor cells (hspcs) for gene replacement. We envision that this non-viral, redosable in vivo hspc gene therapy will enable the expression of encapsulated DNA in target cells while improving safety by avoiding viral integration and potential off-target effects. This therapy has the potential to overcome several challenges posed by ex vivo gene and cell therapies: IT could lower treatment costs, expand treatment availability beyond major academic centers, and reduce patient burden by obviating the need for chemotherapeutic pre-conditioning. With over 6 million people worldwide affected by more than 485 distinct inborn errors of immunity, our in vivo hspc gene therapy platform has the potential to be transformative for many underserved patients. As an initial indication, ada-scid is a disease with established animal models and clinical pathways to reduce development risks. Our coated inverse nanocarriers (cincs) encapsulate nucleic acids in a polymer-lipid hybrid structure that minimize ...
From the federal award record.
Every other federal award to Optimeos Life Sciences, Inc. on record
The federal register lists 6 other awards to the same registry id (UEI LSBKUFPKAHW7), $2,824,077 in all, from 2 agencies.
| Starts | Agency | Amount | Award |
|---|---|---|---|
| 2024-04-09 | National Institutes of Health | $300,000 | Targeted delivery of nucleic acid formulations for in vivo car-treg generation - in this Phase I SBIR, optimeo (R43AI177159) |
| 2023-07-15 | National Science Foundation | $1,500,000 | SBIR Phase II: Formulation of a mrna-based therapy for CTLN1 by inverse flash nanoprecipitation -the broader i (2233286) |
| 2022-06-01 | National Institutes of Health | $287,726 | Highly loaded long-acting depots of therapeutic peptides - peptides can have exquisite potency and selectivity (R43TR004025) |
| 2021-09-05 | National Institutes of Health | $255,351 | Sustained release formulations of therapeutic antibodies - this application seeks to develop a long-acting dep (R43GM142337) |
| 2020-12-15 | National Science Foundation | $256,000 | STTR Phase I: Formulation of a COVID-19 MRNA vaccine by inverse flash nanoprecipitation (2032023) |
| 2019-02-01 | National Science Foundation | $225,000 | STTR Phase I: Sustained delivery of peptides with inverse flash nanoprecipitation (1843551) |
More on Optimeos Life Sciences, Inc.
Optimeos Life Sciences, Inc.'s funding history and team
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Optimeos Life Sciences, Inc.Look up Optimeos Life Sciences, Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.